AroCell is working in the area of cancer diagnostics. The first product is TK 210 hem, for Blood Cancer.
The product is a blood test that identifies cell growth by a unique patented method. It is a biological marker, to be used for prognosis and monitoring different cancer forms, how they develop and evolve. We have a good patent position, according to a recent FTO (Freedom To Operate) study carried out by a US based patent attorney. The company will continue to develop new cancer markers for solid tumors, such as prostate cancer and breast cancer
Description of the company
AroCell is a very promising company in the area of “cell growth and apoptosis” world-wide, and the products have the potential to become gold standard for the determination of cell growth.
Our business idea is to develop and commercialize innovative markers for determination of cell growth (TK 210) and apoptosis, clinically useful for prognosis, monitoring and follow-up of cancer patients.
AroCell are working closely with partners in development, manufacturing, distribution and sales. Key raw materials, clinical documentation, and marketing is the areas where we have our expertise and are building up our own recourses.